DOR BioPharma Reports Second Quarter 2005 Financial Results and Reviews Achievements MIAMI, Aug. 15, 2005 (PRIMEZONE) -- DOR BioPharma, Inc. (AMEX:DOR) ("DOR" or the "Company"), a biopharmaceutical company focused on the development of novel therapeutics and vaccines for unmet...

DOR BioPharma and Dowpharma Enter Into a Joint Development Agreement for BT-VACC, DOR's Oral Vaccine Against Botulinum Toxin Poisoning MIAMI, July 26, 2005 (PRIMEZONE) -- DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") today announced it has entered into a joint development agreement with Dowpharma(sm), a business unit of...

DOR BioPharma and Cambrex Achieve Milestone in the Development and Manufacture of RiVax MIAMI and EAST RUTHERFORD, N.J., July 20, 2005 (PRIMEZONE) -- DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") and a subsidiary of Cambrex Corporation (NYSE:CBM) today announced that they...

DOR BioPharma's Compliance Plan Period Extended by AMEX MIAMI, July 13, 2005 (PRIMEZONE) -- DOR BioPharma, Inc. ("DOR" or the "Company") (AMEX:DOR) announced today that it received notice from the American Stock Exchange ("AMEX") that after review of the...